Practical, structured writing on Chinese MedTech international growth

Country Market

Brazil MedTech Market: Real Opportunity, Real Barriers

China's visa-free access to Brazil, effective May 2026, has renewed interest in the country among Chinese MedTech exporters. The market's appeal is grounded in real fundamentals: top-ten global scale, a public health system covering 215 million people, and increasingly centralized private hospital procurement. Yet the barriers are equally real—ANVISA registration cannot be held directly by foreign entities, combined import tax burdens can reach 60%, and public tender participation requires deep local compliance infrastructure. This article provides a structured assessment of Brazil's market architecture, entry barriers, competitive dynamics, and the conditions under which serious market commitment makes strategic sense.

Field Note·20 Jun 2026·7 min read

Country Market

India MedTech Market: Underestimated, Misread, and Still Worth Entering

India sits in an unusual position for Chinese MedTech companies: large enough to matter strategically, fast-growing enough to reward early movers, yet persistently misunderstood due to limited direct market access. This field note cuts through the noise—neither advocating entry nor dismissing the challenges—and examines India's market segmentation, distribution structure, registration requirements, and the practical steps needed to build a defensible market position.

Field Note·20 Jun 2026·10 min read

Country Market

Mexico MedTech Market: Latin America’s Largest Opportunity—and Its Most Complex Entry

Mexico consistently ranks among the first Latin American markets Chinese medtech companies consider—and for good reason. At an estimated USD 3.5–4 billion in annual medical device sales, it offers scale, strategic reach, and structural demand aligned with many Chinese manufacturers' core product lines. Yet companies that enter without a clear-eyed assessment of COFEPRIS registration timelines, fragmented public procurement channels, and the full-Spanish operating environment often find the market far harder than anticipated. This field note maps the real opportunity logic alongside the structural complexities—so companies can assess readiness before committing resources.

Field Note·20 Jun 2026·8 min read

Country Market

The US MedTech Market: The World’s Biggest Prize — and Its Deepest Trap

At over USD 180 billion and nearly 40% of global MedTech revenue, the US market exerts an almost gravitational pull on Chinese device makers. But that gravity is also the trap. Companies that enter without a clear-eyed understanding of GPO-dominated procurement, clinical evidence requirements, direct-sales economics, and sustained compliance costs rarely survive long enough to find out whether their product could have won. This piece examines the real structure of the US market, draws lessons from Mindray's path, and offers a framework for deciding when — and whether — a Chinese MedTech company is genuinely ready to compete.

Field Note·20 Jun 2026·5 min read